Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:EWTX NASDAQ:OLMA NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$14.62-1.7%$11.22$6.38▼$16.66$1.42B1.471.34 million shs1.03 million shsEWTXEdgewise Therapeutics$14.65+1.4%$13.78$10.60▼$38.12$1.54B0.261.21 million shs1.11 million shsOLMAOlema Pharmaceuticals$5.52-3.8%$4.88$2.86▼$13.93$378.84M1.92854,398 shs298,907 shsSDGRSchrodinger$19.76-0.2%$20.58$16.60▼$28.47$1.45B1.671.16 million shs954,100 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+0.13%+4.35%+37.30%+61.28%-5.89%EWTXEdgewise Therapeutics-1.03%+4.41%+1.33%-0.82%-26.95%OLMAOlema Pharmaceuticals+0.17%+5.32%+18.84%+8.30%-50.86%SDGRSchrodinger+0.76%+2.22%-11.61%-7.70%-4.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals2.7163 of 5 stars3.63.00.00.02.21.70.6EWTXEdgewise Therapeutics2.3223 of 5 stars3.52.00.00.02.72.50.0OLMAOlema Pharmaceuticals1.6635 of 5 stars3.30.00.00.02.82.50.0SDGRSchrodinger2.8535 of 5 stars3.33.00.00.01.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.14Buy$19.6734.52% UpsideEWTXEdgewise Therapeutics 2.91Moderate Buy$40.55176.76% UpsideOLMAOlema Pharmaceuticals 2.67Moderate Buy$24.00334.78% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8340.86% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, EWTX, SDGR, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $20.008/19/2025EWTXEdgewise TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $30.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $29.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.008/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $21.008/11/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell8/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M8.39N/AN/A$0.93 per share15.72EWTXEdgewise TherapeuticsN/AN/AN/AN/A$5.59 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.03 per shareN/ASDGRSchrodinger$207.54M7.01N/AN/A$4.66 per share4.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A243.67N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)Latest OLMA, EWTX, SDGR, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.792.38EWTXEdgewise TherapeuticsN/A28.8728.87OLMAOlema Pharmaceuticals0.0111.0911.09SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%EWTXEdgewise TherapeuticsN/AOLMAOlema Pharmaceuticals91.78%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%EWTXEdgewise Therapeutics23.20%OLMAOlema Pharmaceuticals16.36%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableOLMA, EWTX, SDGR, and AVDL HeadlinesRecent News About These CompaniesDeutsche Bank AG Sells 188,717 Shares of Schrodinger, Inc. $SDGRAugust 27 at 3:29 AM | marketbeat.comAmerican Century Companies Inc. Invests $19.79 Million in Schrodinger, Inc. $SDGRAugust 26 at 3:50 AM | marketbeat.comSchrodinger, Inc. $SDGR Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comSchrödinger: A Complex Story With Many Moving PartsAugust 21, 2025 | seekingalpha.comPublic Sector Pension Investment Board Raises Stake in Schrodinger, Inc. $SDGRAugust 21, 2025 | marketbeat.comCetera Investment Advisers Takes Position in Schrodinger, Inc. $SDGRAugust 21, 2025 | marketbeat.comMorgan Stanley Cuts Schrodinger (NASDAQ:SDGR) Price Target to $19.00August 20, 2025 | marketbeat.comMorgan Stanley Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock PriceAugust 20, 2025 | americanbankingnews.comWhat 4 Analyst Ratings Have To Say About SchrodingerAugust 18, 2025 | benzinga.comTocqueville Asset Management L.P. Sells 23,590 Shares of Schrodinger, Inc. (NASDAQ:SDGR)August 18, 2025 | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Receives $31.20 Consensus Price Target from AnalystsAugust 18, 2025 | americanbankingnews.comSchrodinger (NASDAQ:SDGR) Shares Gap Down - Should You Sell?August 17, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Upgraded to Strong-Buy at BarclaysAugust 17, 2025 | marketbeat.comTejara Capital Ltd Has $2.65 Million Holdings in Schrodinger, Inc. (NASDAQ:SDGR)August 17, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Shares Gap Down - Time to Sell?August 17, 2025 | americanbankingnews.comSchrodinger (NASDAQ:SDGR) Earns Overweight Rating from Analysts at BarclaysAugust 17, 2025 | americanbankingnews.comSchrodinger (SDGR) Gets a Buy from BarclaysAugust 16, 2025 | theglobeandmail.comCraig-Hallum Sticks to Its Buy Rating for Schrodinger (SDGR)August 16, 2025 | theglobeandmail.comSchrodinger (NASDAQ:SDGR) Sets New 12-Month Low - Here's What HappenedAugust 16, 2025 | marketbeat.comSchrodinger downgraded at Citi after clinical program exitAugust 16, 2025 | msn.comCitigroup Downgrades Schrödinger (SDGR)August 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOLMA, EWTX, SDGR, and AVDL Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$14.62 -0.25 (-1.68%) Closing price 04:00 PM EasternExtended Trading$14.29 -0.33 (-2.25%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Edgewise Therapeutics NASDAQ:EWTX$14.65 +0.20 (+1.38%) Closing price 04:00 PM EasternExtended Trading$14.64 -0.01 (-0.07%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Olema Pharmaceuticals NASDAQ:OLMA$5.52 -0.22 (-3.83%) Closing price 04:00 PM EasternExtended Trading$5.67 +0.15 (+2.72%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Schrodinger NASDAQ:SDGR$19.76 -0.03 (-0.15%) Closing price 04:00 PM EasternExtended Trading$19.65 -0.11 (-0.56%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access